Transforming Joint Health: The Promising Role of Connective Tissue Matrix in Osteoarthritis Treatment
The new wave of umbilical cord tissue (UCT) and Connective Tissue Matrix (CTM) products are allograft injectables that are very exciting and proving to be tremendously successful in the treatment of chronic musculoskeletal disorders such as Osteoarthritis (OA).
From the outset, Spruce Health Group (SHG) has implemented cutting-edge therapies and services for our patients in order to bring them back to better musculoskeletal and metabolic health. Our variety of Healthy Mobility treatments helps to fight the most common cause of disability in the United States, Osteoarthritis (according to the CDC). OA has been a focus for SHG since our inception and we continue to offer an evolving scale of treatment options. The team of providers at Spruce continuously monitors the new potential treatments and therapies that are being developed in the field of integrative medicine in order to offer our patients the best-proven options available.
With that in mind, amid these exciting developments, let’s explore the science behind these innovative treatments.
Here are the facts about the new wave of umbilical cord tissue (UCT) and Connective Tissue Matrix (CTM) products:
- These UCT and CTM products are obtained from healthy, carefully screened mothers at the time of normal delivery from the umbilical cord and the chorionic plate of the placenta.
- In addition to a stringent social screening interview, all mothers undergo serology testing to ensure there is no risk for a communicable disease.
- No harm is brought to the mother or her newborn.
- Recovery of the tissue is performed at the time of delivery by trained technicians in a sterile environment.
- Processing is done following all of the current good manufacturing practice regulations of the FDA and the guidelines of the American Association of Tissue Banks (AATB) as well as the American Association of Blood Banks (AABB).
How do Connective Tissue Matrix products promote tissue healing and repair?
Human Connective Tissue Matrix products are able to stimulate the patient’s own regenerative healing mechanisms to progress from a pro-inflammatory environment within the tissue to one of healing and remodeling. This transition allows for connective tissues in the dysfunctional area to restructure, rebuild and regenerate the deficiency or injury by allowing the natural healing components of the patient’s system to be drawn into the appropriate area for healing and providing a native matrix for structural cellular attachment.
SHG provides FDA-approved CTM injections for joint pain relief from OA or injury, with insurance and self-pay options.
There are many options available for alleviating joint pain due to OA or injury, and these injections are proving to be the next step. SHG leads the way for Integrative Medicine in the Denver Metro area, providing innovative and effective therapies for the treatment of OA. Many of these products are FDA approved and are gaining popularity in the mainstream because of the large number of formal studies being performed and the peer-reviewed publications being published. As such, some insurances are beginning to allow coverage for these products but many patients also take advantage of self-pay discounts to get back to their healthy mobility. There are new product options that have a very low price point and still offer amazing pain relief. If you are interested in a risk-free consultation to determine whether or not this cutting edge medical treatment for OA is right for you, give us a call or request a risk free consult at any one of our Denver area locations. We are looking forward to working with you to improve your health and quality of life.